Login
Navigate Fool.com
Will NAVB beat
the market?
Community Rating: 1 Star: Ominous

1.66 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.65
Previous Close $1.66
Daily Range $1.64 - $1.68
52-Week Range $1.11 - $3.31
Market Cap $248.5M
P/E Ratio -4.74
Dividend (Yield) $0.00 (0.0%)
Volume 447,316
Average Daily Volume 990,662
Current FY EPS -$0.34

How do you think NAVB
will perform against the market?

Top NAVB Bull/Bear Pitches

 

TSIF (< 20)
Submitted November 7, 2011

Neoprobe Corp is trending down a little harder than I had expected and my low limit order that's been sitting for a few weeks after the spike from $1.95 to $3.37 during August after a report that the … More

0 Replies Reply Report this Post
 

BuffettJunior1 (< 20)
Submitted October 16, 2011

Extremely overvalued trash stock.

0 Replies Reply Report this Post

News & Commentary Rss Feed

Why Navidea Biopharmaceuticals, Inc. Shares Jumped

Navidea shares ascend after reporting its fourth-quarter earnings results. Here's the one thing investors should really be watching.

Sector Update: Healthcare Shares Flat to Higher Pre-Market; Galena Biopharma up 5% on Enrolling Pati

Sector Update: Healthcare Shares Flat to Higher Pre-Market; Galena Biopharma up 5% on Enrolling Patients in Phase 2 Study

Sector Update: Healthcare

Why Navidea Biopharmaceuticals Inc. Shares Soared

Navidea shares soar after receiving the fast track designation for its lead product. Is now the time to sell or are the good times just getting started?

Sector Update: Healthcare Shares Mixed Pre-Market; Navidea up 19% on Fast Track For Diagnostic Tool

Sector Update: Healthcare

FDA Approves New Alzheimer's Diagnostic Agent but Medicare and Markets Yet to Follow

A look at GE (NYSE: GE) Healthcare's newly-approved Alzheimer's imaging agent, and other players in this space like Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Navidea Biopharmaceuticals (NYSEMRK: NAVB).

3 Diagnostic Stocks That May See Sales Soar Because of Obamacare

The implementation of Obamacare could lead to a surge in preventative care diagnostic tests, which would suit these three health care stocks very well.

SAVE THE DATE: Navidea Biopharmaceuticals to Host Analyst Science Day December 5, 2013 in New York C

Navidea Biopharmaceuticals Announces Additional Results from Lymphoseek® Phase 3 Clinical Trial in H

See More NAVB News...

Sector

Healthcare

Industry

Healthcare Information Services

Navidea Biopharmaceuticals, Inc. (NAVB) Description

Neoprobe Corporation is a biomedical company which is engaged in the development and commercialization of innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of physicians. Website: http://www.navidea.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks